Device Technologies Australia to Help Expand Global MRIdian Adoption by supporting innovation and ingenuity in the medical technology field
Leveraging on-table MR soft tissue imaging, MRIdian allows oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that’s simply unavailable with conventional IGRT technologies.
Combining the latest innovations in precision radiation delivery, ground-breaking MR image guidance, and on-table adaptive therapy, MRIdian represents a new paradigm in radiation oncology.
Device Technologies Australia to Help Expand Global MRIdian Adoption by supporting innovation and ingenuity in the medical technology field
High-Dose Radiation Therapy Enabled by MRIdian’s Daily On-table Adaptation and Gating Beam Control Results in Excellent Retrospective Local Tumor Control, Low Toxicity, and Outstanding Overall Survival versus Non-adaptive Treatment
ViewRay Reports Fourth Quarter and Full Year 2018 Results
CLEVELAND, March 14, 2019 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the fourth quarter and full year ended December 31, 2018.
A new kind of medical technology company—ViewRay® Inc. designs, manufactures and markets MRIdian, the world’s first MRI-Guided radiation therapy system to image and treat cancer patients simultaneously.
Contact Us Today To Learn More Contact
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy